PCRX

Pacira BioSciences Inc. Healthcare - Biotechnology Investor Relations →

YES
36.5% BELOW
↑ Moving away Was -38.5% last week
-15% -10% -5% 0% 5% 10% 15%+
Buy Threshold $33.07
14-Week RSI 49

Pacira BioSciences Inc. (PCRX) closed at $21.00 as of 2026-02-02, trading 36.5% below its 200-week moving average of $33.07. This places PCRX in the extreme value zone. The stock moved further from the line this week, up from -38.5% last week. The 14-week RSI sits at 49, indicating neutral momentum.

Over the past 735 weeks of data, PCRX has crossed below its 200-week moving average 10 times. On average, these episodes lasted 38 weeks. Historically, investors who bought PCRX at the start of these episodes saw an average one-year return of +13.3%.

With a market cap of $903 million, PCRX is a small-cap stock. The company generates a free cash flow yield of 8.7%, which is notably high. Return on equity stands at 2.9%. The stock trades at 1.2x book value.

Share count has increased 3.4% over three years, indicating dilution. This stock also meets the Yartseva multibagger criteria as a small-cap with strong free cash flow yield and reasonable book value.

Over the past 14.2 years, a hypothetical investment of $100 in PCRX would have grown to $196, compared to $673 for the S&P 500. PCRX has returned 4.9% annualized vs 14.4% for the index, underperforming the broader market over this period.

Free cash flow has been growing at a 30.8% compound annual rate, with 4 consecutive years of positive cash generation. A business generating more cash every year while trading below its 200-week moving average is exactly the kind of disconnect value investors look for.

Growth of $100: PCRX vs S&P 500

Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.

What Happens After PCRX Crosses Below the Line?

Across 10 historical episodes, buying PCRX when it crossed below its 200-week moving average produced an average return of +14.0% after 12 months (median -7.0%), compared to +21.5% for the S&P 500 over the same periods. 40% of those episodes were profitable after one year. After 24 months, the average return was +49.5% vs +52.1% for the index.

Each line shows $100 invested at the moment PCRX crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.

Advertisement

Historical Touches

PCRX has crossed below its 200-week MA 10 times with an average 1-year return of +13.3% after recovery.

Crossed BelowRecoveredWeeksMax Depth1-Year ReturnReturn Since Touch
Jan 2012Jan 2012212.9%+139.3%+162.8%
Sep 2015Nov 2015622.6%-22.6%-55.9%
Feb 2016Apr 2016615.7%-22.4%-62.5%
Apr 2016Apr 201915750.7%-10.3%-61.2%
May 2019Jul 2019107.9%-5.2%-52.0%
Aug 2019Nov 20191316.7%+37.4%-50.6%
Mar 2020May 2020924.0%+72.5%-47.7%
Aug 2022Sep 202212.4%-31.3%-59.4%
Sep 2022Sep 202210.4%-37.3%-60.3%
Oct 2022Ongoing174+76.1%Ongoing-59.3%
Average38+13.3%

Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.

Data as of Friday close, 2026-02-02